Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Itulazax (betula verrucosa allergen extract) is a sublingual allergy immunotherapy (AIT) tablet developed and manufactured by ALK-Abelló for the treatment of tree pollen-induced allergic rhinitis and conjunctivitis. [3, 6] The product contains a standardized allergen extract from white birch (*Betula verrucosa*) pollen. [7, 11] It is indicated for patients with moderate-to-severe symptoms not well-controlled by conventional medications, and who have a confirmed sensitization to the birch homologous group of trees (which includes birch, alder, hazel, oak, and others). [7, 11] By administering a small, consistent daily dose of the allergen under the tongue, the therapy works to reprogram the immune system, gradually building tolerance and reducing the severity of allergic reactions to tree pollen. [2, 4, 7] Clinical trials have demonstrated its efficacy in reducing both allergy symptoms and the need for symptom-relieving medication during the entire tree pollen season. [1, 7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betula verrucosa allergen extract.